133918-47-5

Basic information

• Product Name: tetrabenzyl methylenediphosphonate
• Synonyms: tetrabenzyl methylenediphosphonate
• CAS NO: 133918-47-5
• Molecular Weight: 536.501
• Mol File: 133918-47-5.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: tetrabenzyl methylenediphosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: tetrabenzyl methylenediphosphonate(133918-47-5)
• EPA Substance Registry System: tetrabenzyl methylenediphosphonate(133918-47-5)

Safety Data

• Hazardous Substances Data: 133918-47-5(Hazardous Substances Data)

Upstream product

• 15205-57-9 tribenzyl phosphite 
• 166049-87-2 dibenzyl (chloromethyl)phosphonate 
• 1984-15-2 Methylenediphosphonic acid 
• 29134-54-1 tris(benzyloxy)methane 
• 1499-29-2 P,P'-methanediyl-bis-phosphonic acid tetrachloride 
• 100-51-6 benzyl alcohol 
• 114790-35-1 dibenzyl hydroxymethylphosphonate 
• 17176-77-1 Dibenzyl phosphite 
• 19236-58-9 dibenzyl methylphosphonate 
• 538-37-4 dibenzyl phosphochloridate 
• 16001-93-7 tetramethyl methylenediphosphonate 
• 100-44-7 benzyl chloride 
• 253682-73-4 dibenzyl (bromomethyl)phosphonate 

Downstream Products

• 241472-34-4 tetrabenzyl 2-(4-carbomethoxyphenyl)ethane-1,1-diphosphonate 
• 1239480-10-4 C₃₈H₅₂NO₆P 
• 183383-55-3 tetrabenzyl 2-t-butoxycarbonylethane-1,1-diphosphonate 
• 7292-39-9 <methyl>phosphonic acid monobenzyl ester 
• 1984-15-2 Methylenediphosphonic acid 
• 1417995-22-2 C₁₉H₂₁O₃P 
• 1417995-23-3 C₁₉H₂₁O₃P 

Relevant articles and documents

Rh(III)-catalyzed, 1,2,3-triazole-assisted directed C–H coupling with diazo diphosphonates

A mild and efficient procedure was developed for the [Cp?Rh(III)]-catalyzed, 1,2,3-triazole directed C–H coupling with diazomethylene-diphosphonates. This protocol provided a step- and atom-economical protocol for C–C bond formation and led to structurally diverse 2-(1,2,3-triazol-2-yl)benzyl diphosphonates in good to excellent yields.

Bisphosphonate prodrugs: A new synthetic strategy to tetraacyloxymethyl esters of methylenebisphosphonates

A concise and simple method to prepare Cl2C[P(O)(OCH2O2CCMe3)2]2 starting from H2C[P(O)(OMe)2]2 with high selectivity and reasonable yield is developed.

PET bone imaging agent precursor and synthesis method thereof

The invention discloses a PET bone imaging agent precursor, wherein a linking agent tripolyethanol is introduced between a macrocyclic polyamine ligand and a targeting carrier diphosphonic acid, and the diphosphonic acid bone-seeking group with targeting effect can form the macrocyclic polyamine cooperation group of a stable chelate with a plurality of metal nuclides so as to form a bone imaging agent. According to the present invention, the synthesized precursor compound contains the bone-seeking group (diphosphonic acid) and the cooperation group (DOTA), and the two functional groups are linked by PFG3, such that the precursor compound has remarkable structural characteristics; the precursor compound has strong bone-seeking property, and can form a complex (marker) with kinetic and thermodynamic stability with metal nuclides; the marker formed by marking the precursor with different metal nuclides can be used as a bone imaging agent (marked with Cu, Ga and other positron emission metal nuclides) with powerful functions, and can further be used as an ideal bone tumor treatment drug (marked with In, Y, Zr, Sm and other radioactive treatment metal nuclides).

METAL COMPLEX COMPOUND, CANCER THERAPEUTIC COMPOSITION COMPRISING THE METAL COMPLEX COMPOUND AS ACTIVE INGREDIENT, AND INTERMEDIATE FOR PRODUCTION OF THE METAL COMPLEX COMPOUND

A metal complex compound which exhibits a high degree of adsorption to bone or inhibition of cell growth, and is highly effective for therapy of a cancer metastasized to bone and therapy of the primary carcinoma thereof; a therapeutic agent composition for a cancer containing as an active ingredient the metal complex compound or a physiologically acceptable salt thereof; and an intermediate for the metal complex compound are provided. More concretely, a metal complex compound represented by the following General Formula (1): (wherein R1 independently represents C1-C10 alkyl which may be branched or have a substituent; or a C3-C30 cyclic group which may have a substituent; and X represents CHR2, an oxygen atom or NR5); a therapeutic agent composition for a cancer containing it as an active ingredient; and an intermediate for the metal complex compound are provided.